Show simple item record

dc.contributor.authorTabernero, J
dc.contributor.authorVan, CE
dc.contributor.authorBang, Y
dc.contributor.authorFuchs, C
dc.contributor.authorWyrwicz, L
dc.contributor.authorLee, K
dc.contributor.authorKudaba, I
dc.contributor.authorGarrido, M
dc.contributor.authorChung, H
dc.contributor.authorCastro, SH
dc.contributor.authorMansoor, Was
dc.contributor.authorBraghiroli, M
dc.contributor.authorGoekkurt, E
dc.contributor.authorChao, J
dc.contributor.authorWainberg, Z
dc.contributor.authorKher, U
dc.contributor.authorShah, S
dc.contributor.authorKang, S
dc.contributor.authorShitara, K
dc.date.accessioned2020-03-27T09:28:02Z
dc.date.available2020-03-27T09:28:02Z
dc.date.issued2019en
dc.identifier.citationTabernero J, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Ann Oncol. 2019;30 Suppl 4:iv152-iv3.en
dc.identifier.pmid32085055en
dc.identifier.doi10.1093/annonc/mdz183.001en
dc.identifier.urihttp://hdl.handle.net/10541/622838
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz183.001en
dc.titlePembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentVall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spainen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record